The purpose of this study is to access the effect and safety of radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung cancer with harboring active EGFR mutations.
Single Group Assignment
There is one SNP
Inclusion Criteria: - Histologically confirmed diagnosis of non-squamous NSCLC; Stage ⅢA-ⅢB(not suitable for surgery) or stage Ⅳ(only single-site single transfer ); - Untreated patients, or who completed ≤ 2 cycles of first-line chemotherapy (chemotherapy regimen: paclitaxel, docetaxel + cisplatin) within the previous month; - Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R substitution mutation); - Patients must be informed of the investigational nature of the study and must sign an informed consent form; - Presence of at least one measurable/evaluable according to RECIST criteria. --- L858R ---